{"id":49869,"date":"2025-12-03T21:17:38","date_gmt":"2025-12-03T13:17:38","guid":{"rendered":"https:\/\/flcube.com\/?p=49869"},"modified":"2025-12-03T21:17:39","modified_gmt":"2025-12-03T13:17:39","slug":"kura-ziftomenib-sale-triggers-135m-kyowa-kirin-payment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49869","title":{"rendered":"Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment"},"content":{"rendered":"\n<p><strong>Kura Oncology, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/KURA:NASDAQ\">NASDAQ: KURA<\/a>) announced completion of the first US commercial sale of <strong>KOMZIFTI<\/strong> (ziftomenib), triggering a <strong>USD 135 million milestone payment<\/strong> from <strong>Kyowa Kirin<\/strong> under their 2024 licensing agreement. Kura expects to receive payment prior to year\u2011end.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-milestone-amp-financial-impact\">Commercial Milestone &amp; Financial Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>KOMZIFTI (ziftomenib)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adults with relapsed or refractory NPM1\u2011mutated acute myeloid leukemia (AML)<\/td><\/tr><tr><td><strong>FDA Approval<\/strong><\/td><td>November 13, 2025<\/td><\/tr><tr><td><strong>First Commercial Sale<\/strong><\/td><td>December 3, 2025<\/td><\/tr><tr><td><strong>Milestone Payment<\/strong><\/td><td>USD 135 million from Kyowa Kirin<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to USD 1.5 billion (including milestones and royalties)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Kyowa Kirin holds rights outside US; Kura retains US commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism\">Product Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class<\/strong>: Once\u2011daily oral menin inhibitor<\/li>\n\n\n\n<li><strong>Target<\/strong>: NPM1\u2011mutated AML (accounts for ~30% of adult AML cases)<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Disrupts menin\u2011MLL interaction to reverse differentiation block in leukemic blasts<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong>: First approved therapy specifically for NPM1\u2011mutated AML population<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-outlook\">Market Opportunity &amp; Strategic Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Parameter<\/th><th>Value\/Insight<\/th><\/tr><\/thead><tbody><tr><td><strong>AML Incidence<\/strong><\/td><td>~20,000 new cases annually in US; NPM1 mutation in ~6,000 patients<\/td><\/tr><tr><td><strong>Pricing<\/strong><\/td><td>Estimated annual cost of <strong>$300,000\u2011400,000<\/strong> per patient<\/td><\/tr><tr><td><strong>Peak Sales Potential<\/strong><\/td><td>Analysts project <strong>$500\u2011700 million<\/strong> US peak sales<\/td><\/tr><tr><td><strong>Kyowa Kirin Strategy<\/strong><\/td><td>Ex\u2011US launch planned for 2026\u20112027 in Japan, Europe, and Asia\u2011Pacific<\/td><\/tr><tr><td><strong>Revenue Impact<\/strong><\/td><td>$135M payment strengthens Kura&#8217;s cash runway into 2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding milestone payment timing, market penetration, and revenue projections. Actual results may differ due to commercial execution, competitive, and regulatory risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49870,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[16,2267,438,2268],"class_list":["post-49869","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-cancer","tag-kura-oncology","tag-kyowa-kirin","tag-nasdaq-kura"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI (ziftomenib), triggering a USD 135 million milestone payment from Kyowa Kirin under their 2024 licensing agreement. Kura expects to receive payment prior to year\u2011end.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49869\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment\" \/>\n<meta property=\"og:description\" content=\"Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI (ziftomenib), triggering a USD 135 million milestone payment from Kyowa Kirin under their 2024 licensing agreement. Kura expects to receive payment prior to year\u2011end.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49869\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T13:17:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-03T13:17:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49869#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49869\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment\",\"datePublished\":\"2025-12-03T13:17:38+00:00\",\"dateModified\":\"2025-12-03T13:17:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49869\"},\"wordCount\":241,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49869#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0302.webp\",\"keywords\":[\"Cancer\",\"Kura Oncology\",\"Kyowa Kirin\",\"NASDAQ: KURA\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49869#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49869\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49869\",\"name\":\"Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49869#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49869#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0302.webp\",\"datePublished\":\"2025-12-03T13:17:38+00:00\",\"dateModified\":\"2025-12-03T13:17:39+00:00\",\"description\":\"Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI (ziftomenib), triggering a USD 135 million milestone payment from Kyowa Kirin under their 2024 licensing agreement. Kura expects to receive payment prior to year\u2011end.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49869#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49869\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49869#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0302.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49869#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment - Insight, China&#039;s Pharmaceutical Industry","description":"Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI (ziftomenib), triggering a USD 135 million milestone payment from Kyowa Kirin under their 2024 licensing agreement. Kura expects to receive payment prior to year\u2011end.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49869","og_locale":"en_US","og_type":"article","og_title":"Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment","og_description":"Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI (ziftomenib), triggering a USD 135 million milestone payment from Kyowa Kirin under their 2024 licensing agreement. Kura expects to receive payment prior to year\u2011end.","og_url":"https:\/\/flcube.com\/?p=49869","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-03T13:17:38+00:00","article_modified_time":"2025-12-03T13:17:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49869#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49869"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment","datePublished":"2025-12-03T13:17:38+00:00","dateModified":"2025-12-03T13:17:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49869"},"wordCount":241,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49869#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0302.webp","keywords":["Cancer","Kura Oncology","Kyowa Kirin","NASDAQ: KURA"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49869#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49869","url":"https:\/\/flcube.com\/?p=49869","name":"Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49869#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49869#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0302.webp","datePublished":"2025-12-03T13:17:38+00:00","dateModified":"2025-12-03T13:17:39+00:00","description":"Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI (ziftomenib), triggering a USD 135 million milestone payment from Kyowa Kirin under their 2024 licensing agreement. Kura expects to receive payment prior to year\u2011end.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49869#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49869"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49869#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0302.webp","width":1080,"height":608,"caption":"Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49869#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49869"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49869\/revisions"}],"predecessor-version":[{"id":49871,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49869\/revisions\/49871"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49870"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}